Please use this identifier to cite or link to this item:
|Title:||Targeting of a conformationally exposed, tumor-specific epitope of EGFR as a strategy for cancer therapy.|
|Authors:||Gan, Hui K;Burgess, Antony W;Clayton, Andrew H A;Scott, Andrew M|
|Affiliation:||Joint Austin-Ludwig Medical Oncology Unit, Austin Hospital, Australia.|
|Citation:||Cancer Research 2012; 72(12): 2924-30|
|Abstract:||Epidermal growth factor receptor (EGFR) and its most common extracellular mutant, EGFRvIII, are important therapeutic targets in multiple cancer types. A number of monoclonal antibodies and small-molecule inhibitors against these receptors are now used for anticancer treatments. New insights into the structure and function of these receptors illustrate how they can be targeted in novel ways, with expected improvements in the therapeutic efficacy. Monoclonal antibody 806 (mAb806) is an antibody that targets a conformationally exposed epitope of wild-type EGFR when it is overexpressed on tumor cells or in the presence of oncogenic mutations such as EGFRvIII. The mechanism of action of mAb806, which allows for EGFR inhibition without normal tissue toxicity, creates opportunities for combination therapy and strongly suggests mAb806 will be a superior targeted delivery system for antitumor agents. Targeting of the epitope for mAb806 also appears to be an improved strategy to inhibit tumors that express EGFRvIII. This concept of conformational epitope targeting by antibodies reflects an underlying interplay between the structure and biology of different conformational forms of the EGFR family.|
|Internal ID Number:||22659454|
Antibodies, Monoclonal.immunology.therapeutic use
Receptor, Epidermal Growth Factor.immunology.metabolism
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.